Hydralazine and isosorbide dinitrate in heart failure: Historical perspective, mechanisms, and future directions

Circulation

Volumn 123, Issue 21, 2011, Pages 2414-2422

  Cole, Robert T ^a   Kalogeropoulos, Andreas P ^a   Georgiopoulou, Vasiliki V ^a   Gheorghiade, Mihai ^b   Quyyumi, Arshed ^a   Yancy, Clyde ^c   Butler, Javed ^a,d  

^a EMORY UNIVERSITY   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^d EMORY UNIVERSITY HOSPITAL   (United States)

Author keywords

heart failure; hydralazine; isosorbide dinitrate; nitric oxide

Indexed keywords

ENALAPRIL; HYDRALAZINE; HYDRALAZINE PLUS ISOSORBIDE DINITRATE; ISOSORBIDE DINITRATE; NITRIC OXIDE; PLACEBO; PRAZOSIN;

ACUTE HEART FAILURE; AREA UNDER THE CURVE; CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); DRUG POTENTIATION; GENETIC HETEROGENEITY; HEART EJECTION FRACTION; HEART FAILURE; HEART VENTRICLE FUNCTION; HUMAN; MAXIMUM PLASMA CONCENTRATION; MORTALITY; OXIDATION REDUCTION REACTION; OXYGEN CONSUMPTION; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RACE DIFFERENCE; REVIEW; SEX DIFFERENCE;

AFRICAN AMERICANS; ANIMALS; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; EXERCISE TOLERANCE; FORECASTING; HEART FAILURE; HUMANS; HYDRALAZINE; ISOSORBIDE DINITRATE; STROKE VOLUME;

EID: 79958141073     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.110.012781     Document Type: Review

References (109)

1. Cohn JN, Franciosa JA. Vasodilator therapy of cardiac failure: (first of two parts). N Engl J Med. 1977;297:27-31. (Pubitemid 8114597)
2. Cohn JN. Blood pressure and cardiac performance. Am J Med. 1973; 55:351-361.
3. Cohn JN. Vasodilator therapy for heart failure: the influence of impedance on left ventricular performance. Circulation. 1973;48:5-8.
4. Imperial ES, Levy MN, Zieske H. Outflow resistance as an independent determinant of cardiac performance. Circ Res. 1961;9:1148-1155.
5. Sonnenblick EH, Downing SE. Afterload as a primary determinant of ventricular performance. Am J Physiol. 1963;204:604-610.
6. Franciosa JA, Limas CJ, Guiha NH, Rodriguera E, Cohn JN. Improved left ventricular function during nitroprusside infusion in acute myocardial infarction. Lancet. 1972;1:650-654.
7. Guiha NH, Cohn JN, Mikulic E, Franciosa JA, Limas CJ. Treatment of refractory heart failure with infusion of nitroprusside. N Engl J Med. 1974;291:587-592.
8. Franciosa JA, Cohn JN. Effects of minoxidil on hemodynamics in patients with congestive heart failure. Circulation. 1981;63:652-657. (Pubitemid 11139876)
9. Franciosa JA, Mikulic E, Cohn JN, Jose E, Fabie A. Hemodynamic effects of orally administered isosorbide dinitrate in patients with congestive heart failure. Circulation. 1974;50:1020-1024.
10. Franciosa JA, Pierpont G, Cohn JN. Hemodynamic improvement after oral hydralazine in left ventricular failure: a comparison with nitroprusside infusion in 16 patients. Ann Intern Med. 1977;86:388-393. (Pubitemid 8078945)
11. Miller RR, Awan NA, Maxwell KS, Mason DT. Sustained reduction of cardiac impedance and preload in congestive heart failure with the antihypertensive vasodilator prazosin. N Engl J Med. 1977;297: 303-307. (Pubitemid 8161784)
12. Schreiber R, Maier PT, Gunnar RM, Loeb HS. Hemodynamic improvement following a single dose of oral phentolamine: administration in patients with chronic low output cardiac failure. Chest. 1979; 76:571-575. (Pubitemid 10131004)
13. Massie B, Chatterjee K, Werner J, Greenberg B, Hart R, Parmley WW. Hemodynamic advantage of combined administration of hydralazine orally and nitrates nonparenterally in the vasodilator therapy of chronic heart failure. Am J Cardiol. 1977;40:794-801. (Pubitemid 8225612)
14. Pierpont GL, Cohn JN, Franciosa JA. Combined oral hydralazine-nitrate therapy in left ventricular failure: hemodynamic equivalency to sodium nitroprusside. Chest. 1978;73:8-13. (Pubitemid 8271991)
15. Cohn JN, Archibald DG, Ziesche S, Franciosa JA, Harston WE, Tristani FE, Dunkman WB, Jacobs W, Francis GS, Flohr KH, Goldman S, Cobb FR, Shah PM, Saunders R, Fletcher RD, Loeb HS, Hughes CV, Baker B. Effect of vasodilator therapy on mortality in chronic congestive heart failure: results of a Veterans Administration cooperative study. N Engl J Med. 1986;314:1547-1552. (Pubitemid 16114684)
16. Cohn JN, Johnson G, Ziesche S, Cobb F, Francis G, Tristani F, Smith R, Dunkman WB, Loeb H, Wong M, Bhat G, Goldman S, Fletcher RD, Doherty J, Hughes CV, Carson P, Cintron G, Shabetai R, Haakenson C. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med. 1991;325: 303-310.
17. Sankar P, Kahn J. BiDil: race medicine or race marketing. Health Aff (Millwood). 2005;July-Dec(suppl Web exclusives):W5-455-W5-463.
18. Temple R. Center for Drug Evaluation and Research approval package for: Application number 20-727. http://www.accessdata.fda.gov/ drugsatfda-docs/nda/ 2005/020727-S000-Bidil-APPROV-BLE.pdf. Accessed April 27, 2011.
19. Dries DL, Exner DV, Gersh BJ, Cooper HA, Carson PE, Domanski MJ. Racial differences in the outcome of left ventricular dysfunction. N Engl J Med. 1999;340:609-616. (Pubitemid 29093720)
20. Carson P, Ziesche S, Johnson G, Cohn JN. Racial differences in response to therapy for heart failure: analysis of the vasodilator-heart failure trials: Vasodilator-Heart Failure Trial Study Group. J Card Fail. 1999;5:178-187. (Pubitemid 29449255)
21. Temple R, Stockbridge NL. BiDil for heart failure in black patients: The U.S. Food and Drug Administration perspective. Ann Intern Med. 2007; 146:57-62. (Pubitemid 351650321)
22. Taylor AL, Ziesche S, Yancy C, Carson P, D'Agostino R Jr, Ferdinand K, Taylor M, Adams K, Sabolinski M, Worcel M, Cohn JN. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med. 2004;351:2049-2057.
23. Minutes of the Cardiovascular and Renal Drugs Advisory Committee. Volume .2. http://www.fda.gov/ohrms/dockets/ac/cder05.html#cardiovascularRenal. Accessed April 27, 2011.
24. Bloche MG. Race-based therapeutics. N Engl J Med. 2004;351: 2035-2037. (Pubitemid 39482493)
25. Schwartz RS. Racial profiling in medical research. N Engl J Med. 2001;344:1392-1393. (Pubitemid 32378397)
26. Bibbins-Domingo K, Fernandez A. BiDil for heart failure in black patients: implications of the U.S. Food and drug administration approval. Ann Intern Med. 2007;146:52-56. (Pubitemid 351650320)
27. Franciosa JA, Taylor AL, Cohn JN, Yancy CW, Ziesche S, Olukotun A, Ofili E, Ferdinand K, Loscalzo J, Worcel M. African-American Heart Failure Trial (A-HeFT): rationale, design, and methodology. J Card Fail. 2002;8:128-135. (Pubitemid 34857277)
28. Cardillo C, Kilcoyne CM, Cannon RO 3rd, Panza JA. Attenuation of cyclic nucleotide-mediated smooth muscle relaxation in blacks as a cause of racial differences in vasodilator function. Circulation. 1999; 99:90-95. (Pubitemid 29035962)
29. Kahn DF, Duffy SJ, Tomasian D, Holbrook M, Rescorl L, Russell J, Gokce N, Loscalzo J, Vita JA. Effects of black race on forearm resistance vessel function. Hypertension. 2002;40:195-201. (Pubitemid 34840098)
30. Kalinowski L, Dobrucki IT, Malinski T. Race-specific differences in endothelial function: predisposition of African Americans to vascular diseases. Circulation. 2004;109:2511-2517. (Pubitemid 38720549)
31. Stein CM, Lang CC, Nelson R, Brown M, Wood AJ. Vasodilation in black Americans: attenuated nitric oxide-mediated responses. Clin Pharmacol Ther. 1997;62:436-443. (Pubitemid 27475228)
32. Vita JA. Nitric oxide and vascular reactivity in African American patients with hypertension. J Card Fail. 2003;9:S199-S204. (Pubitemid 41096360)
33. Hare JM. Nitroso-redox balance in the cardiovascular system. N Engl J Med. 2004;351:2112-2114. (Pubitemid 39482505)
34. Ignarro L, Buga GM, Wood KS, Byrns RE, Chaudhuri G. Endothelium-derived relaxing factor released from artery and vein is nitric oxide. Proc Natl Acad Sci USA. 1987;84:9265-9269.
35. Kelly RA, Balligand JL, Smith TW. Nitric oxide and cardiac function. Circ Res. 1996;79:363-380. (Pubitemid 26276897)
36. Kubes P, Suzuki M, Granger DM. Nitric oxide: an endogenous modulator of leukocyte adhesion. Proc Natl Acad Sci USA. 1991;88: 4651-4655. (Pubitemid 21914599)
37. Prabhu SD. Nitric oxide protects against pathological ventricular remodeling: reconsideration of the role of NO in the failing heart. Circ Res. 2004;94:1155-1157. (Pubitemid 38656401)
38. Keith M, Geranmayegan A, Sole MJ, Kurian R, Robinson A, Omran AS, Jeejeebhoy KN. Increased oxidative stress in patients with congestive heart failure. J Am Coll Cardiol. 1998;31:1352-1356. (Pubitemid 28219127)
39. McMurray J, Chopra M, Abdullah I, Smith WE, Dargie HJ. Evidence of oxidative stress in chronic heart failure in humans. Eur Heart J. 1993; 14:1493-1498. (Pubitemid 24002712)
40. Yucel D, Aydogdu S, Cehreli S, Saydam G, Canatan H, Senes M, Cigdem Topkaya B, Nebioglu S. Increased oxidative stress in dilated cardiomyopathic heart failure. Clin Chem. 1998;44:148-154. (Pubitemid 28042480)
41. Stamler JS, Lamas S, Fang FC. Nitrosylation. The prototypic redox-based signaling mechanism. Cell. 2001;106:675-683. (Pubitemid 32900659)
42. Xu L, Eu JP, Meissner G, Stamler JS. Activation of the cardiac calcium release channel (ryanodine receptor) by poly-S-nitrosylation. Science. 1998;279:234-237. (Pubitemid 28103882)
43. Gonzalez DR, Treuer AV, Castellanos J, Dulce RA, Hare JM. Impaired S-nitrosylation of the ryanodine receptor caused by xanthine oxidase activity contributes to calcium leak in heart failure. J Biol Chem. 2010; 285:28938-28945.
44. Foster MW, McMahon TJ, Stamler JS. S-nitrosylation in health and disease. Trends Mol Med. 2003;9:160-168. (Pubitemid 36626705)
45. Viner RI, Williams TD, Schoneich C. Nitric oxide-dependent modification of the sarcoplasmic reticulum Ca-ATPase: localization of cysteine target sites. Free Radic Biol Med. 2000;29:489-496.
46. Wink DA, Mitchell JB. Chemical biology of nitric oxide: insights into regulatory, cytotoxic, and cytoprotective mechanisms of nitric oxide. Free Radic Biol Med. 1998;25:434-456. (Pubitemid 28390299)
47. Drexler H, Hayoz D, Munzel T, Hornig B, Just H, Brunner HR, Zelis R. Endothelial function in chronic congestive heart failure. Am J Cardiol. 1992;69:1596-1601.
48. Katz SD, Biasucci L, Sabba C, Strom JA, Jondeau G, Galvao M, Solomon S, Nikolic SD, Forman R, LeJemtel TH. Impaired endothelium-mediated vasodilation in the peripheral vasculature of patients with congestive heart failure. J Am Coll Cardiol. 1992;19:918-925.
49. Kojda G, Harrison D. Interactions between NO and reactive oxygen species: pathophysiological importance in atherosclerosis, hypertension, diabetes and heart failure. Cardiovasc Res. 1999;43:562-571. (Pubitemid 29369255)
50. Kubo SH, Rector TS, Bank AJ, Williams RE, Heifetz SM. Endothelium-dependent vasodilation is attenuated in patients with heart failure. Circulation. 1991;84:1589-1596.
51. Treasure CB, Vita JA, Cox DA, Fish RD, Gordon JB, Mudge GH, Colucci WS, Sutton MG, Selwyn AP, Alexander RW. Endotheliumdependent dilation of the coronary microvasculature is impaired in dilated cardiomyopathy. Circulation. 1990;81:772-779. (Pubitemid 20090372)
52. Katz SD. Mechanisms and implications of endothelial dysfunction in congestive heart failure. Curr Opin Cardiol. 1997;12:259-264. (Pubitemid 27252533)
53. Meyer B, Mortl D, Strecker K, Hulsmann M, Kulemann V, Neunteufl T, Pacher R, Berger R. Flow-mediated vasodilation predicts outcome in patients with chronic heart failure: comparison with B-type natriuretic peptide. J Am Coll Cardiol. 2005;46:1011-1018. (Pubitemid 41316508)
54. Drexler H, Hornig B. Endothelial dysfunction in human disease. J Mol Cell Cardiol. 1999;31:51-60. (Pubitemid 29078218)
55. Ramsey MW, Goodfellow J, Jones CJ, Luddington LA, Lewis MJ, Henderson AH. Endothelial control of arterial distensibility is impaired in chronic heart failure. Circulation. 1995;92:3212-3219.
56. Arstall MA, Sawyer DB, Fukazawa R, Kelly RA. Cytokine-mediated apoptosis in cardiac myocytes: the role of inducible nitric oxide synthase induction and peroxynitrite generation. Circ Res. 1999;85:829-840. (Pubitemid 29504158)
57. Levrand S, Vannay-Bouchiche C, Pesse B, Pacher P, Feihl F, Waeber B, Liaudet L. Peroxynitrite is a major trigger of cardiomyocyte apoptosis in vitro and in vivo. Free Radic Biol Med. 2006;41:886-895. (Pubitemid 44262482)
58. Pacher P, Beckman JS, Liaudet L. Nitric oxide and peroxynitrite in health and disease. Physiol Rev. 2007;87:315-424. (Pubitemid 46217686)
59. Brown GC, Borutaite V. Nitric oxide, mitochondria, and cell death. IUBMB Life. 2001;52:189-195. (Pubitemid 33731572)
60. Androne AS, Hryniewicz K, Hudaihed A, Dimayuga C, Yasskiy A, Qureshi G, Katz SD. Comparison of metabolic vasodilation in response to exercise and ischemia and endothelium-dependent flow-mediated dilation in African-American versus non-African-American patients with chronic heart failure. Am J Cardiol. 2006;97:685-689. (Pubitemid 43255040)
61. McNamara DM, Tam SW, Sabolinski ML, Tobelmann P, Janosko K, Venkitachalam L, Ofili E, Yancy C, Feldman AM, Ghali JK, Taylor AL, Cohn JN, Worcel M. Endothelial nitric oxide synthase (NOS3) polymorphisms in African Americans with heart failure: Results from the A-HeFT trial. J Card Fail. 2009;15:191-198.
62. McNamara DM, Holubkov R, Postava L, Ramani R, Janosko K, Mathier M, MacGowan GA, Murali S, Feldman AM, London B. Effect of the Asp298 variant of endothelial nitric oxide synthase on survival for patients with congestive heart failure. Circulation. 2003;107: 1598-1602. (Pubitemid 36397327)
63. Heiat A, Gross CP, Krumholz HM. Representation of the elderly, women, and minorities in heart failure clinical trials. Arch Intern Med. 2002;162:1682-1688.
64. Lindenfeld J, Krause-Steinrauf H, Salerno J. Where are all the women with heart failure? J Am Coll Cardiol. 1997;30:1417-1419. (Pubitemid 27486455)
65. Petrie MC, Dawson NF, Murdoch DR, Davie AP, McMurray JJ. Failure of women's hearts. Circulation. 1999;99:2334-2341. (Pubitemid 29201142)
66. Taylor AL, Lindenfeld J, Ziesche S, Walsh MN, Mitchell JE, Adams K, Tam SW, Ofili E, Sabolinski ML, Worcel M, Cohn JN. Outcomes by gender in the African-American Heart Failure trial. J Am Coll Cardiol. 2006;48:2263-2267. (Pubitemid 44855413)
67. Hokamaki J, Kawano H, Yoshimura M, Soejima H, Miyamoto S, Kajiwara I, Kojima S, Sakamoto T, Sugiyama S, Hirai N, Shimomura H, Nagayoshi Y, Tsujita K, Shioji I, Sasaki S, Ogawa H. Urinary biopyrrins levels are elevated in relation to severity of heart failure. J Am Coll Cardiol. 2004;43:1880-1885. (Pubitemid 38622530)
68. Testa M, Yeh M, Lee P, Fanelli R, Loperfido F, Berman JW, LeJemtel TH. Circulating levels of cytokines and their endogenous modulators in patients with mild to severe congestive heart failure due to coronary artery disease or hypertension. J Am Coll Cardiol. 1996;28:964-971. (Pubitemid 26348163)
69. Ungvari Z, Gupte SA, Recchia FA, Batkai S, Pacher P. Role of oxidative-nitrosative stress and downstream pathways in various forms of cardiomyopathy and heart failure. Curr Vasc Pharmacol. 2005;3: 221-229. (Pubitemid 40933045)
70. Khan SA, Lee K, Minhas KM, Gonzalez DR, Raju SV, Tejani AD, Li D, Berkowitz DE, Hare JM. Neuronal nitric oxide synthase negatively regulates xanthine oxidoreductase inhibition of cardiac excitationcontraction coupling. Proc Natl Acad Sci USA. 2004;101: 15944-15948. (Pubitemid 39507906)
71. Paulus WJ, Vantrimpont PJ, Shah AM. Acute effects of nitric oxide on left ventricular relaxation and diastolic distensibility in humans: assessment by bicoronary sodium nitroprusside infusion. Circulation. 1994;89:2070-2078. (Pubitemid 24142783)
72. Prendergast BD, Sagach VF, Shah AM. Basal release of nitric oxide augments the Frank-Starling response in the isolated heart. Circulation. 1997;96:1320-1329. (Pubitemid 27344239)
73. Sydow K, Daiber A, Oelze M, Chen Z, August M, Wendt M, Ullrich V, Mulsch A, Schulz E, Keaney JF Jr, Stamler JS, Munzel T. Central role of mitochondrial aldehyde dehydrogenase and reactive oxygen species in nitroglycerin tolerance and cross-tolerance. J Clin Invest. 2004;113: 482-489. (Pubitemid 38544192)
74. Munzel T, Kurz S, Rajagopalan S, Thoenes M, Berrington WR, Thompson JA, Freeman BA, Harrison DG. Hydralazine prevents nitroglycerin tolerance by inhibiting activation of a membrane-bound NADH oxidase: a new action for an old drug. J Clin Invest. 1996;98:1465-1470. (Pubitemid 26322073)
75. Adams KF Jr, Fonarow GC, Emerman CL, LeJemtel TH, Costanzo MR, Abraham WT, Berkowitz RL, Galvao M, Horton DP. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100 000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J. 2005;149:209-216. (Pubitemid 40348525)
76. Gheorghiade M, Abraham WT, Albert NM, Greenberg BH, O'Connor CM, She L, Stough WG, Yancy CW, Young JB, Fonarow GC. Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure. JAMA. 2006;296: 2217-2226. (Pubitemid 44708052)
77. Peterson PN, Rumsfeld JS, Liang L, Albert NM, Hernandez AF, Peterson ED, Fonarow GC, Masoudi FA. A validated risk score for in-hospital mortality in patients with heart failure from the American Heart Association Get With the Guidelines program. Circ Cardiovasc Qual Outcomes. 2010;3:25-32.
78. Mullens W, Abrahams Z, Francis GS, Skouri HN, Starling RC, Young JB, Taylor DO, Tang WH. Sodium nitroprusside for advanced lowoutput heart failure. J Am Coll Cardiol. 2008;52:200-207. (Pubitemid 351915785)
79. Mullens W, Abrahams Z, Francis GS, Sokos G, Starling RC, Young JB, Taylor DO, Tang WH. Usefulness of isosorbide dinitrate and hydralazine as add-on therapy in patients discharged for advanced decompensated heart failure. Am J Cardiol. 2009;103:1113-1119.
80. Butler J, Chomsky DB, Wilson JR. Pulmonary hypertension and exercise intolerance in patients with heart failure. J Am Coll Cardiol. 1999;34:1802-1806.
81. Ghio S, Gavazzi A, Campana C, Inserra C, Klersy C, Sebastiani R, Arbustini E, Recusani F, Tavazzi L. Independent and additive prognostic value of right ventricular systolic function and pulmonary artery pressure in patients with chronic heart failure. J Am Coll Cardiol. 2001;37:183-188. (Pubitemid 32051736)
82. Lam C, Roger V, Rodeheffer R, Borlaug B, Enders F, Redfield M. Pulmonary hypertension in heart failure with preserved ejection fraction: a community-based study. J Am Coll Cardiol. 2009;53:1119-1126.
83. Leung C, Moondra V, Catherwood E, Andrus B. Prevalence and risk factors of pulmonary hypertension in patients with elevated pulmonary venous pressure and preserved ejection fraction. Am J Cardiol. 2010; 106:284-286.
84. Konstam MA, Salem DN, Isner JM, Zile MR, Kahn PC, Bonin JD, Cohen SR, Levine HJ. Vasodilator effect on right ventricular function in congestive heart failure and pulmonary hypertension: end-systolic pressure-volume relation. Am J Cardiol. 1984;54:132-136. (Pubitemid 14085363)
85. Gavazzi A, Ghio S, Scelsi L, Campana C, Klersy C, Serio A, Raineri C, Tavazzi L. Response of the right ventricle to acute pulmonary vasodilation predicts the outcome in patients with advanced heart failure and pulmonary hypertension. Am Heart J. 2003;145:310-316. (Pubitemid 36207953)
86. Abramson SV, Burke JF, Kelly JJ Jr, Kitchen JG 3rd, Dougherty MJ, Yih DF, McGeehin FC 3rd, Shuck JW, Phiambolis TP. Pulmonary hypertension predicts mortality and morbidity in patients with dilated cardiomyopathy. Ann Intern Med. 1992;116:888-895. (Pubitemid 23034779)
87. Kjaergaard J, Akkan D, Iversen KK, Kjoller E, Kober L, Torp-Pedersen C, Hassager C. Prognostic importance of pulmonary hypertension in patients with heart failure. Am J Cardiol. 2007;99:1146-1150. (Pubitemid 46578202)
88. de Groote P, Millaire A, Foucher-Hossein C, Nugue O, Marchandise X, Ducloux G, Lablanche J. Right ventricular ejection fraction is an independent predictor of survival in patients with moderate heart failure. J Am Coll Cardiol. 1998;32:948-954. (Pubitemid 28459583)
89. Di Salvo T, Mathier M, Semigran M, Dec G. Preserved right ventricular ejection fraction predicts exercise capacity and survival in advanced heart failure. J Am Coll Cardiol. 1995;25:1143-1153.
90. Field M, Solomon S, Lewis E, Kramer D, Baughman K, Stevenson L, Tedrow U. Right ventricular dysfunction and adverse outcome in patients with advanced heart failure. J Card Fail. 2006;12:616-620. (Pubitemid 44512147)
91. Juilliere Y, Barbier G, Feldmann L, Grentzinger A, Danchin N, Cherrier F. Additional predictive value of both left and right ventricular ejection fractions on long-term survival in idiopathic dilated cardiomyopathy. Eur Heart J. 1997;18:276-280. (Pubitemid 27107590)
92. Moraes DL, Colucci WS, Givertz MM. Secondary pulmonary hypertension in chronic heart failure: the role of the endothelium in pathophysiology and management. Circulation. 2000;102:1718-1723.
93. Blitzer M, Loh E, Roddy M, Stamler J, Creager M. Endothelium-derived nitric oxide regulates systemic and pulmonary vascular resistance during acute hypoxia in humans. J Am Coll Cardiol. 1996;28:591-596. (Pubitemid 26288638)
94. Cooper C, Landzberg M, Anderson T, Charbonneau F, Creager M, Ganz P, Selwyn A. Role of nitric oxide in the local regulation of pulmonary vascular resistance in humans. Circulation. 1996;93:266-271. (Pubitemid 26031484)
95. Stamler J, Loh E, Roddy M, Currie K, Creager M. Nitric oxide regulates basal systemic and pulmonary vascular resistance in healthy humans. Circulation. 1994;89:2035-2040. (Pubitemid 24142778)
96. Ontkean M, Gay R, Greenberg B. Diminished endothelium-derived relaxing factor activity in an experimental model of chronic heart failure. Circ Res. 1991;69:1088-1096.
97. Porter TR, Taylor DO, Cycan A, Fields J, Bagley CW, Pandian NG, Mohanty PK. Endothelium-dependent pulmonary artery responses in chronic heart failure: influence of pulmonary hypertension. J Am Coll Cardiol. 1993;22:1418-1424. (Pubitemid 23316368)
98. Cooper CJ, Jevnikar FW, Walsh T, Dickinson J, Mouhaffel A, Selwyn AP. The influence of basal nitric oxide activity on pulmonary vascular resistance in patients with congestive heart failure. Am J Cardiol. 1998; 82:609-614. (Pubitemid 28397662)
99. Packer M, Medina N, Yushak M. Contrasting hemodynamic responses in severe heart failure: comparison of captopril and other vasodilator drugs. Am Heart J. 1982;104:1215-1223. (Pubitemid 13152843)
100. Unverferth DV, Mehegan JP, Magorien RD, Unverferth BJ, Leier CV. Regression of myocardial cellular hypertrophy with vasodilator therapy in chronic congestive heart failure associated with idiopathic dilated cardiomyopathy. Am J Cardiol. 1983;51:1392-1398. (Pubitemid 13133085)
101. Cohn JN, Tam SW, Anand IS, Taylor AL, Sabolinski ML, Worcel M. Isosorbide dinitrate and hydralazine in a fixed-dose combination produces further regression of left ventricular remodeling in a welltreated black population with heart failure: results from A-HeFT. J Card Fail. 2007;13:331-339. (Pubitemid 46978420)
102. Temporelli P, Corra U, Imparato A, Bosimini E, Scapellato F, Giannuzzi P. Reversible restrictive left ventricular diastolic filling with optimized oral therapy predicts a more favorable prognosis in patients with chronic heart failure. J Am Coll Cardiol. 1998;31:1591-1597. (Pubitemid 28273303)
103. Hirata K, Adji A, Vlachopoulos C, O'Rourke M. Effect of sildenafil on cardiac performance in patients with heart failure. Am J Cardiol. 2005; 96:1436-1440. (Pubitemid 41566628)
104. Levy W, Mozaffarian D, Linker D, Sutradhar S, Anker S, Cropp A, Anand I, Maggioni A, Burton P, Sullivan M, Pitt B, Poole-Wilson P, Mann D, Packer M. The Seattle Heart Failure Model: prediction of survival in heart failure. Circulation. 2006;113:1424-1433. (Pubitemid 43739439)
105. Cho G, Marwick T, Kim H, Kim M, Hong K, Oh D. Global 2-dimensional strain as a new prognosticator in patients with heart failure. J Am Coll Cardiol. 2009;54:618-624.
106. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, Jessup M, Konstam MA, Mancini DM, Michl K, Oates JA, Rahko PS, Silver MA, Stevenson LW, Yancy CW. 2009 Focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation. 2009;119: e391-e479.
107. Yancy CW, Fonarow GC, Albert NM, Curtis AB, Stough WG, Gheorghiade M, Heywood JT, McBride ML, Mehra MR, O'Connor CM, Reynolds D, Walsh MN. Adherence to guideline-recommended adjunctive heart failure therapies among outpatient cardiology practices (findings from IMPROVE HF). Am J Cardiol. 2010;105:255-260.
108. Yancy CW, Abraham WT, Albert NM, Clare R, Stough WG, Gheorghiade M, Greenberg BH, O'Connor CM, She L, Sun JL, Young JB, Fonarow GC. Quality of care of and outcomes for African Americans hospitalized with heart failure: findings from the OPTIMIZE-HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients With Heart Failure) registry. J Am Coll Cardiol. 2008;51: 1675-1684. (Pubitemid 351626409)
109. Tam SW, Sabolinski ML, Worcel M, Packer M, Cohn JN. Lack of bioequivalence between different formulations of isosorbide dinitrate and hydralazine and the fixed-dose combination of isosorbide dinitrate/hydralazine: the V-HeFT paradox. Clin Pharmacokinet. 2007;46:885-895. (Pubitemid 47443312)